Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

Susan F. Slovin, MD, PhD
Published: Friday, Apr 21, 2017



Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

There have been tremendous strides looking at different immune-based platforms, states Slovin. An approach being evaluated is the PROSTVAC platform, which is a transgene of PSA in a fowlpox vector given with 3 immune stimulatory molecules.

There are a variety of molecules to which immunotherapies are being developed including VISTA, LAG-3, FoxP3, explains Slovin.
 


Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

There have been tremendous strides looking at different immune-based platforms, states Slovin. An approach being evaluated is the PROSTVAC platform, which is a transgene of PSA in a fowlpox vector given with 3 immune stimulatory molecules.

There are a variety of molecules to which immunotherapies are being developed including VISTA, LAG-3, FoxP3, explains Slovin.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x